Lumicell is an investigational drug and device system currently in clinical trials to determine the ability of the system to detect some forms of cancer during surgery.  The system is being developed to help surgeons identify cancer during a surgical procedure, which would allow them to take action during surgeries to improve patient outcomes.


The company’s lead product, the Lumicell System, is in late-stage development for breast cancer surgery. It features an investigational onco-fluorescent agent and a handheld imaging device that enable cancer surgeons to see and remove cancer cells in real-time during operations. The Lumicell System was designed and developed by MIT engineers in partnership with leading breast cancer surgeons to fit seamlessly within the existing surgical workflow. Lumicell is investigating the use of its therapy in patients undergoing surgery for breast cancer, ovarian cancer, prostate cancer, brain cancer, colorectal, esophageal and pancreatic cancers.












CAUTION – New Drug and Investigational device. Limited by Federal (or United States) law to investigational use.